Broad spectrum antiviral nucleosides-Our best hope for the future.

4区 化学 Q3 Chemistry Annual Reports in Medicinal Chemistry Pub Date : 2021-01-01 DOI:10.1016/bs.armc.2021.09.001
Katherine L Seley-Radtke, Joy E Thames, Charles D Waters
{"title":"Broad spectrum antiviral nucleosides-Our best hope for the future.","authors":"Katherine L Seley-Radtke,&nbsp;Joy E Thames,&nbsp;Charles D Waters","doi":"10.1016/bs.armc.2021.09.001","DOIUrl":null,"url":null,"abstract":"<p><p>The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides have been shown to inhibit multiple viruses due to the conserved nature of many viral enzyme binding sites. Thus, it is somewhat surprising that up until very recently, many researchers focused more on \"one bug one drug,\" rather than trying to target multiple viruses given those similarities. This attitude is now changing due to the realization that we need to be proactive rather than reactive when it comes to combating emerging and reemerging infectious diseases. A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein.</p>","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"57 ","pages":"109-132"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553659/pdf/","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Reports in Medicinal Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/bs.armc.2021.09.001","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 8

Abstract

The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides have been shown to inhibit multiple viruses due to the conserved nature of many viral enzyme binding sites. Thus, it is somewhat surprising that up until very recently, many researchers focused more on "one bug one drug," rather than trying to target multiple viruses given those similarities. This attitude is now changing due to the realization that we need to be proactive rather than reactive when it comes to combating emerging and reemerging infectious diseases. A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
广谱抗病毒核苷——我们对未来的最大希望。
目前,许多研究人员的重点已转向开发具有广谱抑制剂潜力的治疗方法,这种抑制剂可以针对特定家族中的许多病毒,也可以跨越多个病毒家族。这将使我们能够建立一个可用于下一次疫情爆发的治疗药物库。在这方面,核苷几十年来一直是抗病毒治疗的基石。正如本文所详述的,由于许多病毒酶结合位点的保守性,许多核苷已被证明可以抑制多种病毒。因此,令人惊讶的是,直到最近,许多研究人员更多地关注“一种病毒一种药物”,而不是试图针对多种病毒,因为这些相似之处。这种态度现在正在改变,因为我们认识到,在防治新出现和再出现的传染病方面,我们需要积极主动,而不是被动被动。本文简要总结了以前表现出广谱活性的突出核苷类似物,现在重新引起了人们的兴趣,以及目前正在研究的针对SARS-CoV-2和其他病毒的新类似物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.
期刊最新文献
The challenges and opportunities of developing small molecule inhibitors of MraY. The limited role of most circRNAs as sponges for microRNAs. Preface Anno 2021: Which antivirals for the coming decade? Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1